David Brems, PhD
David Brems, PhD
David Brems, PhD, is a recognized expert in the field of protein stability, formulation, structure, and folding. He has been a leader in the Biopharma development industry for over 30 years working for Amgen, Eli Lilly, and Upjohn. He has made critical contributions to the development of the following marketed products; Humalog, Neulasta, Aranesp, Nplate, Prolia, Vectibix, and Xgeva. He has extensive experience in solving and preventing pharmaceutical development challenges, protein formulation automation technology, and optimum formulation resource strategies.

Dr, Brems has authored over 80 publications in top tier journals, has 10 issued patents, and currently is a consultant. He has been an invited speaker at numerous international scientific meetings, universities, and FDA workshops. He has been an Adjunct Professor in the Dept. of Molecular and Cellular Medicine at Texas A&M University and the Dept. of Pharmaceutical Sciences at the University of Colorado and has served as a member of dissertation committees for several students. He has organized numerous sessions for international scientific societies and has served on executive advisory councils for various multicenter scientific initiatives. He is the recipient of the Eli Lilly Presidents Award and Ebert Prize by the American Pharmacists Association.

Dr. Brems received his PhD from the Dept. of Biochemistry at the University of Utah and was a postdoctoral fellow at the University of Iowa and Stanford. He has been a successful laboratory scientist and executive leader over small and large groups.